一种经验证的新型连续预后指数用于儿童急性淋巴细胞白血病的分层医疗
该研究基于4项近期试验数据建立并验证了连续预后指数PIUKALL,该指数整合初诊白细胞计数、治疗前细胞遗传学和诱导结束微小残留病,能个体化预测复发风险并改善风险分层。
要点
- PIUKALL是整合初诊白细胞、细胞遗传学和诱导后MRD的连续预后指数。
- PIUKALL定义的四组5年复发率在发现和验证队列中相似且区分明显。
- 与传统算法相比,PIUKALL提高了所有终点的预测一致性指数。
核心结论
- PIUKALL能准确预测儿童ALL患者的结局,并为未来研究提供更灵活的风险分组方法。
研究设计与样本
- 研究利用UKALL2003、COALL-03、DCOG-ALL10和NOPHO-ALL2008四项试验数据,建立发现队列(n=2405)和验证队列(n=2313)。
- 采用多因素Cox回归在发现队列中确定包含初诊白细胞计数、治疗前细胞遗传学和诱导结束微小残留病的最小模型。
主要发现
- PIUKALL与复发风险相关,并在独立队列中得到验证。
- PIUKALL定义的四组5年复发率在发现队列为:低危3%(95%CI 2%-4%)、标危8%(95%CI 6%-10%)、中危17%(95%CI 14%-21%)、高危48%(95%CI 36%-60%)。
- 验证队列四组5年复发率为:低危4%(95%CI 3%-6%)、标危9%(95%CI 6%-12%)、中危17%(95%CI 14%-21%)、高危35%(95%CI 24%-48%)。
- 使用PIUKALL进行风险分层较传统算法提高了所有终点的的一致性指数。
- 受试者工作特征曲线下面积分析证实PIUKALL分组在预测结局上显著优于各试验所用算法。
关键数值与推荐
- PIUKALL包含初诊白细胞计数、治疗前细胞遗传学和诱导结束微小残留病三个变量。
- 发现队列低危、标危、中危、高危的5年复发率分别为3%、8%、17%、48%。
- 验证队列低危、标危、中危、高危的5年复发率分别为4%、9%、17%、35%。
临床怎么用
- PIUKALL可作为儿童ALL患者个体化风险分层工具,辅助临床治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Risk stratification is essential for the delivery of optimal treatment in childhood acute lymphoblastic leukemia. However, current risk stratification algorithms dichotomize variables and apply risk factors independently, which may incorrectly assume identical associations across biologically heterogeneous subsets and reduce statistical power. Accordingly, we developed and validated a prognostic index (PIUKALL) that integrates multiple risk factors and uses continuous data. We created discovery (n = 2405) and validation (n = 2313) cohorts using data from 4 recent trials (UKALL2003, COALL-03, DCOG-ALL10, and NOPHO-ALL2008). Using the discovery cohort, multivariate Cox regression modeling defined a minimal model including white cell count at diagnosis, pretreatment cytogenetics, and end-of-induction minimal residual disease. Using this model, we defined PIUKALL as a continuous variable that assigns personalized risk scores. PIUKALL correlated with risk of relapse and was validated in an independent cohort. Using PIUKALL to risk stratify patients improved the concordance index for all end points compared with traditional algorithms. We used PIUKALL to define 4 clinically relevant risk groups that had differential relapse rates at 5 years and were similar between the 2 cohorts (discovery: low, 3% [95% confidence interval (CI), 2%-4%]; standard, 8% [95% CI, 6%-10%]; intermediate, 17% [95% CI, 14%-21%]; and high, 48% [95% CI, 36%-60%; validation: low, 4% [95% CI, 3%-6%]; standard, 9% [95% CI, 6%-12%]; intermediate, 17% [95% CI, 14%-21%]; and high, 35% [95% CI, 24%-48%]). Analysis of the area under the curve confirmed the PIUKALL groups were significantly better at predicting outcome than algorithms employed in each trial. PIUKALL provides an accurate method for predicting outcome and more flexible method for defining risk groups in future studies.
引用
- Enshaei A, O'Connor D, Bartram J, et al. A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia. Blood. 2020. PMID: 32315382. doi:10.1182/blood.2019003191
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。